Figure 3 Clinical trial design in charged-particle therapy (CPT)

Slides:

Advertisements

Similar presentations

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,

Advertisements

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Response after initial increase in total tumour burden

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Figure 1 Concept of the therapeutic index

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 2 Multiscale modelling in oncology

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Generations of cancer vaccine antigens

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Monitoring clonal evolution using liquid biopsies

Figure 2 Three-step approach to the assessment and management

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Copy-number variations in multiple myeloma

Figure 5 Identification of mucinous carcinoma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 6 Double opposed-field irradiation of an idealized geometry

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 1 Proposed treatment algorithm for advanced gastroesophageal cancer based on publish recommendations Figure 1 | Proposed treatment algorithm for.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 CAR-T-cell design

Figure 2 Examples of histopathological validation

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 2 The association between CD8+ T‑cell density of the tumour

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 The biological effects of charged particles

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Drug cycling with collateral sensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Figure 3 Algorithm for the determination of the clinical

chemotherapy for patients with MC versus those with AC

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 The dynamic nature of resistance mechanisms can be

Figure 2 Nonmalignant tissue can be spared from radiation

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Summary of overall survival by Kaplan–Meier

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Median monthly launch price of a new anticancer drug,

Figure 1 Translocations involved in multiple myeloma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Key features of gastric cancer subtypes according to The Cancer Genome Atlas (TCGA) Figure 2 | Key features of gastric cancer subtypes according.

Figure 2 Host immune responses, not the radiosensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Palliative-care-referral patterns

Figure 2 The imaging biomarker roadmap

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Variations between planned and delivered doses of radiation

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 7 Overview of the methodological processes for

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Radiogenomics analysis can reveal relationships

Figure 1 Overview of the imaging biomarker roadmap

Figure 3 Craniospinal irradiation proton therapy for medulloblastoma

Figure 3 Determination of the primary site

Figure 1 Gene-expression quantification methods

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Presentation transcript:

Figure 3 Clinical trial design in charged-particle therapy (CPT) Figure 3 | Clinical trial design in charged-particle therapy (CPT). General procedure in CPT trials: patients in the control arm generally receive X-rays, unless the aim of the trial is to compare different charged particles (for example, protons versus carbon ions). Trials of X-rays versus protons or carbon ions compare different physical dose- distributions and the end point can be decreased toxicity (if the same dose to tumour is prescribed), or increased local disease control (if trials prescribe isotoxic doses). Trials comparing protons to carbon ions will have similar physical dose-distribution, and the main end point will be the effect of biological effectiveness. Durante, M. et al. (2017) Charged-particle therapy in cancer: clinical uses and future perspectives Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2017.30